In this article, Gregory Vistnes outlines why Antitrust Agencies care about clinical integration, an issue that might seem primarily an issue of concern to the healthcare community and not antitrust enforcers, and how the agencies typically evaluate the competitive significance of clinical integration.
A tale of two stakeholder groups in regulating healthcare AI
Despite significant spending on healthcare in the US, the industry is slow to adopt AI technology that can cut costs and improve efficiency. In this CPI...